



Diese Meldung wurde von presstext ausgedruckt und ist unter <https://www.presstext.com/news/20251217002> abrufbar.

pta20251217002

Business news for the stock market

# Leo International Precision Health Aktiengesellschaft: Acquisition of stakes in first six portfolio companies completed

Planegg / Martinsried, Germany (pta002/17.12.2025/00:25 UTC+1)

- Transaction marks official start of Leo International Precision Health's growth platform
- LIPH offers investors access to the expanding Asian and global healthcare and life sciences market with strategic focus on AI-driven precision health assets across medtech, healthtech, biotech and healthcare services.
- Portfolio valued at EUR 108 million

Martinsried/Planegg, Germany, **December 17, 2025** – Leo International Precision Health AG ("LIPH" or the "Company", WKN: 549060, ticker symbol: LEOW), an investment and holding company focused on AI-driven precision health assets, announces the completion of the acquisition of its first six portfolio companies. The transaction consolidates LIPH's majority shareholdings across key precision health assets and represents a total portfolio valuation of EUR 108 million.

The acquisitions and the accompanying capital increase through contribution in kind as previously disclosed in the Company's ad-hoc announcement dated November 25, 2025, were implemented and registered in the commercial register of the Düsseldorf Local Court on December 16, 2025. As such, the Company's share capital increased by EUR 50,000.00 to EUR 550,000.00 through a capital increase of EUR 50,000.00 by issuing 50,000 new no-par value bearer shares with full profit participation rights as of January 1, 2025, in exchange for contributions in kind.

The six acquired companies form the foundation of LIPH's integrated, AI-driven healthcare ecosystem and span medtech, healthtech, biotech and healthcare services. As set out in today's ad-hoc publication, the following entities have now been contributed and integrated into LIPH:

- amiko AI Biomedical Limited, Taiwan (51.00%)
- Danner Laboratory, Inc., USA (51.00%)
- Immune Anima Inc. (UHO Wellness), Taiwan (67.32%)
- Pathomics Health Pte. Ltd., Singapore (51.00%)
- Rehne Biotech (Australia) Pty Ltd, Australia (51.00%)
- Wankang Medical Group (Hong Kong) Co., Limited (Dr. Pain), Hong Kong (100.00%)

With these majority holdings now secured, LIPH has established the first building block of its broader portfolio strategy, creating a synergistic and scalable platform for innovation, operational integration, and long-term value creation.

**Joshua Lo, CEO of LIPH, commented:** "Finalizing our first acquisitions marks a defining moment in LIPH's evolution. With this step, we are laying the foundation for Europe's first integrated AI-driven healthcare ecosystem, linking medtech, healthtech, biotech and healthcare services under a unified platform. By taking majority stakes, we ensure alignment, control, and the ability to unlock data-driven synergies across our portfolio. Today is more than a transaction milestone; it is the beginning of LIPH's growth trajectory and long-term investment success."

LIPH will continue to pursue targeted acquisitions and active development of its portfolio, leveraging international capital markets to support scalable asset growth. The Company's business model focuses on acquiring and developing attractive opportunities, enhancing their value, and selectively spinning them off, thereby generating shareholder value through asset reconfiguration, revenue growth, licensing, and royalties.

### **About Leo International Precision Health AG**

Leo International Precision Health AG ("LIPH", ticker symbol: LEOW) is a holding company building Europe's first integrated AI-driven healthcare ecosystem. With a strategic focus on AI-driven precision health assets across medtech, healthtech, biotech and healthcare services. LIPH offers investors access to the expanding Asian and global healthcare and life sciences market. By reconfiguring assets, LIPH integrates technology, data, and operations to accelerate medical outcomes and portfolio performance.

For more information, please visit our website.

### **Contact:**

#### **Leo International Precision Health AG**

Am Klopferspitz 19

82152 Planegg / Martinsried

[vorstand@spobag-ag.de](mailto:vorstand@spobag-ag.de)

### **Media Support:**

#### **MC Services AG**

Pamela Keck, Katja Arnold, Kaja Skorka

[news@mc-services.eu](mailto:news@mc-services.eu)

+49 (0)89- 210 228-0

(end)

<b>Emitter:</b>	Leo International Precision Health Aktiengesellschaft Am Klopferspitz 19 82152 Planegg / Martinsried Germany
<b>Contact Person:</b>	Phillip Campbell
<b>E-Mail:</b>	<a href="mailto:vorstand@spobag-ag.de">vorstand@spobag-ag.de</a>
<b>ISIN(s):</b>	DE0005490601 (Share)
<b>Stock Exchange(s):</b>	Regulated Market in Dusseldorf, Frankfurt